Bayer to Present Data from Cardiovascular, Kidney and Stroke Clinical Trials at ESC 2026

Aug. 20, 2026 — Bayer has announced that 11 oral presentations across its cardiovascular, kidney, and secondary stroke prevention programs will be featured at the European Society of Cardiology (ESC) Congress 2026 in Munich, Germany, Aug. 28-31, 2026.

For the first time, full results from the Phase III REVEAL study, which evaluated the investigational PET radiotracer I 124 evuzamitide for the sensitivity and specificity of cardiac amyloidosis based on visual scan interpretation. 

Also, a new analysis from the previously presented Phase III OCEANIC-STROKE trial will explore how participant characteristics affected their response to asundexian in secondary stroke prevention.

Data from two late-breaking presentations will be featured, including a pre-specified subgroup analysis from the Phase III FIND-CKD trial, which evaluated KERENDIA (finerenone) in patients with CKD without diabetes and hypertensive nephropathy and data from the INFINITY pooled analysis evaluating the efficacy and safety of KERENDIA in patients with chronic kidney disease (CKD) with and without a history of atherosclerotic cardiovascular disease (ASCVD). 

Why This Matters

“Bayer is committed to further researching and providing resources to support prevention, early diagnosis, and management for people with heart and kidney conditions, as well as stroke. These data reflect Bayer’s commitment to that cause,” said Robert Perkins, MD, Vice President, US Medical Affairs. "We look forward to advancing the scientific dialogue across the spectrum of cardiovascular and cerebrovascular disease care."

Cardiovascular, Kidney and Stroke Presentations 

Cardiac Amyloidosis

• A phase 3, open-label, multicenter study of investigational positron emission tomography (PET) radiotracer iodine 124 evuzamitide in the assessment of patients with suspected cardiac amyloidosis

Heart Failure

• Finerenone and serum sodium in patients with heart failure and mildly reduced or preserved ejection fraction: an analysis of FINEARTS-HF

• Time in blood pressure range and cardiovascular outcomes in HFmrEF/HFpEF: a pooled participant-level analysis of four large-scale trials

• Cardiovascular-kidney-metabolic overlap and finerenone in heart failure: insights from the FINEARTS-HF Trial

• GenePHIT Phase 2 baseline characteristics: a double blind, placebo-controlled trial to assess safety and efficacy of AB-1002 gene therapy in heart failure with reduced ejection fraction

Secondary Stroke Prevention

• Dual antiplatelet therapy (DAPT) during the first 90 days post-randomisation in OCEANIC-STROKE: participant characteristics and interaction with asundexian

Chronic Kidney Disease

• Effects of finerenone in patients with hypertensive nephropathy
• Efficacy and safety of finerenone in patients with chronic kidney disease and cardiovascular diseases: An individual participant data pooled analysis (INFINITY)
• Systolic blood pressure variability and effect of finerenone treatment in patients with chronic kidney disease and type 2 diabetes: a FIDELITY analysis
• Simultaneous versus sequential initiation of CKM therapies: an indirect comparison of CONFIDENCE and FIDELITY
• Finerenone with empagliflozin according to body mass index in chronic kidney disease and type 2 diabetes
• Real-world effectiveness and safety of finerenone in patients with chronic kidney disease and type 2 diabetes in the United States: A FOUNTAIN platform analysis

To learn more about Bayer go to www.bayer.com and https://pharma.bayer.com/